logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Dermatitis Atopic

    FiltersReset Filters
    40 results

    • adbry

      (tralokinumab-ldrm)
      LEO Pharma Inc.
      Usage: ADBRY is indicated for treating moderate-to-severe atopic dermatitis in adults and pediatric patients aged 12 and older when topical therapies are ineffective or unsuitable. It may be used with or without topical corticosteroids.

    • cibinqo

      (abrocitinib)
      U.S. Pharmaceuticals
      Usage: CIBINQO is indicated for treating refractory, moderate-to-severe atopic dermatitis in adults and patients aged 12 and older, when the condition is not adequately managed by other systemic therapies or when those treatments are unsuitable. Co-use with other JAK inhibitors or biologics is not recommended.

    • cibinqo

      (abrocitinib)
      Pfizer Laboratories Div Pfizer Inc
      Usage: CIBINQO is indicated for treating adults and pediatric patients aged 12 and older with refractory, moderate-to-severe atopic dermatitis not adequately controlled by other systemic treatments, including biologics, or when those therapies are inadvisable. It is not recommended for use with other JAK inhibitors or immunosuppressants.

    • desonide

      (Desonide)
      Cintex Services, LLC
      Usage: Desonide Gel, 0.05% is indicated for treating mild to moderate atopic dermatitis in patients aged 3 months and older. It should be used for the shortest duration necessary to achieve results, not exceeding 4 consecutive weeks, due to potential HPA axis suppression.

    • dexamethasone

      (Dexamethasone)
      Prasco Laboratories
      Usage: The drug is indicated for severe allergies, dermatologic and endocrine disorders, gastrointestinal and hematologic diseases, neurogenic conditions, neoplastic diseases, and various conditions across respiratory, ophthalmic, renal, and rheumatic diseases. It serves to manage symptoms or provide palliative care in specific cases.

    • dexamethasone

      (dexamethasone)
      Amneal Pharmaceuticals NY LLC
      Usage: This drug is indicated for severe allergic conditions, dermatologic and endocrine disorders, gastrointestinal issues, hematologic disorders, certain cancers, acute nervous system conditions, ocular inflammation, renal diseases, respiratory conditions, and as adjunctive therapy for rheumatic disorders. It addresses various severe and chronic health issues unresponsive to standard treatments.

    • dexamethasone

      (Dexamethasone)
      Rising Pharma Holdings, Inc.
      Usage: This drug is indicated for various conditions, including endocrine and rheumatic disorders, collagen diseases, severe allergic states, ophthalmic and respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, and certain miscellaneous conditions, as well as for diagnostic testing of adrenocortical hyperfunction.

    • dexamethasone sodium phosphate

      (Dexamethasone Sodium Phosphate)
      Mylan Institutional LLC
      Usage: This drug is indicated for various conditions, including adrenal insufficiencies, rheumatic disorders, collagen diseases, severe allergic reactions, ophthalmic, gastrointestinal, respiratory, hematologic, and neoplastic diseases, and for reducing edema. It can be administered intravenously, intramuscularly, intra-articularly, or intralesionally, depending on the condition.

    • dexamethasone sodium phosphate

      (Dexamethasone Sodium Phosphate)
      Amneal Pharmaceuticals LLC
      Usage: This drug is indicated for various conditions, including endocrine and rheumatic disorders, allergic states, gastrointestinal diseases, respiratory diseases, hematologic disorders, and certain dermatologic and ophthalmic diseases. It can be administered intravenously, intramuscularly, intra-articular, or intralesionally for acute episodes and management of chronic conditions.

    • dexamethasone sodium phosphate

      (Dexamethasone Sodium Phosphate)
      Civica, Inc.
      Usage: This drug is indicated for various conditions, including endocrine disorders (like adrenocortical insufficiency), rheumatic and collagen diseases, severe allergic reactions, dermatologic and gastrointestinal diseases, respiratory issues, hematologic conditions, neoplastic diseases, and neurological disorders. It can be administered intravenously, intramuscularly, intra-articularly, or intralesionally as appropriate.